



Substitute Form PTO-1449 (Modified)  (37 CFR § 1.89(b))	U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 13425-122001	Application No. 10/622,055
	Information Disclosure Statement by Applicant (Use several sheets if necessary)			
	Applicant Cernerud et al.			
	Filing Date July 17, 2003		Group Art Unit 4614 1624	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
ZT	AA	5,134,149	07/28/92	Carr, et al.	514	317	
ZT	AB	5,538,974	07/23/96	Ogawa et al.	514	253	
ZT	AC	6,143,792	11/07/00	Cattelin	514	640	
ZT	AD	6,358,977	03/19/02	Carlsson	514	317	


Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
ZT	AE	EP 0522226A1	12/20/91	EPO	—	—		
ZT	AF	EP 0695545A1	06/14/95	EPO	—	—		
ZT	AG	WO 00/12090	03/09/00	WIPO	—	—		
ZT	AH	WO 01/89498 A2	11/29/01	WIPO	—	—		

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
ZT	AI	Abbot, F.V., et al., "Activation of 5-HT _{2A} Receptors Potentiates Pain Produced by Inflammatory Mediators", <i>Neuropharmacology</i> , vol. 35(1), pp. 99-110, 1996.
ZT	AJ	Apelqvist, J., et al., "Ketanserin in the treatment of diabetic foot ulcer with severe peripheral vascular disease", <i>International Angiology</i> , vol. 9, pp. 120-124, 1990.
ZT	AK	Bush, L.R., et al., "The Role of the Endothelium in Arterial Thrombosis and the Influence of Antithrombotic Therapy", <i>Drug Development Research</i> , vol. 7, pp. 319-340, 1986.
ZT	AL	Cohen, M.L., "Canine, but not rat bladder contracts to serotonin via activation of 5HT ₂ receptors", <i>The Journal of Urology</i> , vol. 143, pp. 1037-1040, 1990.
ZT	AM	Costagliola, C., et al., "Effect of tropical ketanserin administration on intraocular pressure", <i>British Journal of Ophthalmology</i> , vol. 77, pp. 344-348, 1993.
ZT	AN	Danton, G., et al., "Endothelium-targeted pharmacotherapeutics for the treatment of stroke", <i>Current Opinion in Investigational Drugs</i> , vol. 3(6), pp. 896-904, 2002.
ZT	AO	Dietrich, W.D., et al., "Effect of the serotonin antagonist ketanserin on the hemodynamic and morphological consequences of thrombotic infarction", <i>Journal of Cerebral Blood Flow and Metabolism</i> , vol. 9, pp. 812-820, 1989.
ZT	AP	Dursun, S.M., et al., "An exploratory approach to the serotonergic hypothesis of depression: bridging the synaptic gap", <i>Medical Hypotheses</i> , vol. 56(2), pp. 235-243, 2001.
ZT	AQ	Furukawa, K., et al., "Therapeutic effects of sarpogrelate hydrochloride (MCI-9042) on chronic arterial occlusive diseases: a double-blind comparison with ticlopidine hydrochloride", <i>J. Clin. Ther. Med.</i> 1991, 7, 1747-1770.
ZT	AR	Gelders, Y.G., "Thymosthenic agents, a novel approach in the treatment of schizophrenia", <i>British Journal of Psychiatry</i> , vol. 155(suppl.), pp. 33-36, 1989.

Examiner Signature 	Date Considered 21 AUGUST 2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13425-122001	Application No. 10/622,055
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Cernerud et al.	
		Filing Date July 17, 2003	Group Art Unit 1614 1624
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
ZT	AS	Hara, N., et al., "Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models", <i>Thrombosis and Haemostasis</i> , vol. 66(4), pp. 484-488, 1991.
ZT	AT	Hemmeter, U., et al., "Schlafstorungen bei chronischen schmerzen und generalisierter tendomyopathie", <i>Schweiz Med Wochenschr</i> , vol. 125, pp. 2391-2397, 1995. (Abstract Only)
ZT	AU	Hotta, N., et al., "Effects of the 5-HT _{2A} receptor antagonist sarpogrelate in diabetic patients with complications", <i>Clin Drug Invest</i> , vol. 18(3), pp. 199-207, 1999.
ZT	AV	Ichiyangi, N., et al., "Changed responsiveness of the detrusor in rabbits with alloxan induced hyperglycemia: Possible role of 5-hydroxytryptamine for diabetic bladder dysfunction", <i>The Journal of Urology</i> , vol. 168, pp. 303-307, 2002.
ZT	AW	Ishimura, E., et al., "Therapeutic effect of sarpogrelate, a new 5-hydroxytryptamine receptor 2A antagonist, on diabetic nephropathy and neuropathy", <i>Nephron</i> , vol. 76, pp. 227-229, 1997.
ZT	AX	Jackson, J., et al., "Enhancement of [m-methoxy 3H]MDL100907 binding to 5HT _{2A} receptors in cerebral cortex and brain stem of streptozotocin induced diabetic rats", <i>Molecular and Cellular Biochemistry</i> , vol. 199, pp. 81-85, 1999.
ZT	AY	Kaplan, S.A., et al., "Urodynamic findings in patients with diabetic cystopathy", <i>The Journal of Urology</i> , vol. 153, pp. 342-344, 1995.
ZT	AZ	Kihara, H., et al., "Antithrombotic activity of AT-1015, a potent 5-HT _{2A} receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time", <i>European Journal of Pharmacology</i> , vol. 433, pp. 157-162, 2001.
ZT	AAA	Kim, H.J., et al., "Acute effects of serotonin on rat bladder contractility", <i>Urologia Internationalis</i> , vol. 68, pp. 44-48, 2002.
ZT	ABB	Kobori, S., et al., "Effect of 5-hydroxytryptamine _{2A} receptor antagonist on the development of diabetic nephropathy in early stage", <i>Diabetes Mellitus: Recent Advances for the 21st Century</i> , pp. 283-286, 2000.
ZT	ACC	Kodama, M., et al., "Influence of 5-hydroxytryptamine and the effect of a new serotonin receptor antagonist (sarpogrelate) on detrusor smooth muscle of streptozotocin-induced diabetes mellitus in the rat", <i>International Journal of Urology</i> , vol. 7, pp. 231-235, 2000.
ZT	ADD	Leysen, D., et al., "5-HT ₂ antagonists: a concept for the treatment of schizophrenia", <i>Current Pharmaceutical Design</i> , vol. 3, pp. 367-390, 1997.
ZT	AEE	Malyszko, J., et al., "Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes", <i>Thrombosis Research</i> , vol. 75(5), pp. 569-576, 1994.
ZT	AFF	Mano, T., et al., "The effect of anplag (sarpogrelate HCl), new selective 5-HT ₂ antagonist on intraocular pressure in rabbits", <i>Investigative Ophthalmology & Visual Science</i> , vol. 36(4), pp. 3322-3309, 1995.
ZT	AGG	Martinez-De Jesus, F.R., et al., "Randomized single-blind trial of topical ketanserin for healing acceleration of diabetic foot ulcers", <i>Archives of Medical Research</i> , vol. 28(1), pp. 95-99, 1997.
ZT	AHH	Menendez, V., et al., "Urodynamic evaluation in simultaneous insulin-dependent diabetes mellitus and end stage renal disease", <i>The Journal of Urology</i> , vol. 155, pp. 2001-2004, 1996.
ZT	AII	Mermoud, A., et al., "Le traitement du glaucome a pression normale avec un antagoniste des recepteurs S2 de la serotonine, le naftidrofuryl (praxilen)", <i>Klin. Mbl. Augenheilk.</i> , vol. 198, pp. 332-334, 1991.
ZT	AJJ	Mermoud, A., et al., "Double-blind study in the treatment of normal tension glaucoma with naftidrofuryl", <i>Ophthalmologica</i> , vol. 201, pp. 145-151, 1990.

Examiner Signature 	Date Considered 21 AUGUST 2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13425-122001	Application No. 10/622,055
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Cernerud et al.	
		Filing Date July 17, 2003	Group Art Unit 1614 1624
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
ZT	AKK	Nabeshima, T., et al., "Effect of naftidrofuryl oxalate on 5-HT ₂ receptors in mouse brain: evaluation based on quantitative autoradiography and head-twitch response", <i>European Journal of Pharmacology</i> , vol. 223, pp. 109-115, 1992.
ZT	ALL	Obata, H., et al., "Antinociception in rat by sarpogrelate, a selective 5-HT _{2A} receptor antagonist, is peripheral", <i>European Journal of Pharmacology</i> , vol. 404, pp. 95-102, 2000.
ZT	AMM	Ogawa, S., et al., "The 5-HT ₂ receptor antagonist sarpogrelate reduces urinary and plasma levels of thromboxane A2 and urinary albumin excretion in non-insulin-dependent diabetes mellitus patients", <i>Clinical and Experimental Pharmacology and Physiology</i> , vol. 26, pp. 461-464, 1999.
ZT	ANN	Otake, T., et al., "Bone atrophy in complex regional pain syndrome patients measured by microdensitometry", <i>Canadian Journal of Anesthesiology</i> , vol. 45(9), pp. 831-838, 1998.
ZT	AOO	Pietraszek, M.H., et al., "Blood serotonergic mechanisms in type 2 (non-insulin-dependent) diabetes mellitus", <i>Thrombosis Research</i> , vol. 66, pp. 765-774, 1992.
ZT	APP	Pietraszek, M.H., et al., "Enhanced platelet response to serotonin in diabetes mellitus in relationship to vascular complications", <i>Thromb. Haemost.</i> 1991, 65, 985 (Abstract Only)
ZT	AQQ	Pietraszek, M.H., et al., "The effect of MCI-9042 on serotonin-induced platelet aggregation in type 2 diabetes mellitus", <i>Thrombosis Research</i> , vol. 70, pp. 131-138, 1993.
ZT	ARR	Radulovacki, M., et al., "Ketanserin, a 5-HT ₂ receptor antagonist, reduces sleep apneas in rats", <i>Research Communications in Biological Psychology and Psychiatry</i> , vol. 26 (1,2), 2001.
ZT	ASS	Robertson, S.C., et al., "Effects of serotonin (5-HT) and selective 5-HT receptor antagonists on regional cerebral blood flow after middle cerebral artery occlusion", <i>Surgical Forum</i> , pp. 561-563.
ZT	ATT	Saxena, P.R., et al., "Excitatory 5-hydroxytryptamine receptors in the cat urinary bladder are of the M- and 5-HT ₂ -type", <i>Journal of Autonomic Pharmacology</i> , vol. 5, pp. 101-107, 1985.
ZT	AUU	Schechter, L.E., et al., "Serotonergic antidepressants: current and future perspectives", <i>CPNS Investigational Drugs</i> , vol. 7(4), pp. 432-447, 1999.
ZT	AVV	Sorbera, L.A., et al., "MDL-100907", <i>Drugs of the Future</i> , vol. 23(9), pp. 955-965, 1998.
ZT	AWW	Stratz, T., et al., "Blockierung der 5-HT ₂ -rezeptoren – ein neues behandlungsspringzip der generalisierten tendomyopathie (fibromyalgie)?", <i>Zeitschrift für Rheumatologie</i> , vol. 50, pp. 21-22, 1991. (Abstract Only)
ZT	AXX	Sugimoto, S., et al., "Characteristics of 5-HT _{2A} receptors in the bladder smooth muscle of diabetic rats", <i>Nihon. Univ. J. Med.</i> , vol. 43, pp. 141-152, 2001.
ZT	AYY	Sumiyoshi, T., et al., "The effect of streptozotocin-induced diabetes on dopamine ₂ , serotonin 1A, and serotonin 2A receptors in the rat brain", <i>Neuropsychopharmacology</i> , vol. 16(3), 183-190, 1997.
ZT	AZZ	Takei, I., et al., "Effects of the 5-HT ₂ receptor antagonist sarpogrelate on diabetic vascular disease", <i>Diabetes Research</i> , vol. 34, pp. 239-246, 1999.
ZT	AAAA	Takenaka, H., et al., "The effect of anglag (saprogrepalte HCL), novel selective 5-HT ₂ antagonist on intraocular presser in glaucoma patients", <i>Invest. Ophthalmol. Vis. Sci.</i> 1995, 36, S734. (Abstract Only)
ZT	ABBB	Takimoto, Y., et al., "The effect of 5-HT ₂ antagonist for urinary frequency symptom on diabetes mellitus patients", <i>Jpn. J. Urol.</i> vol. 90(8), pp. 731-740, 1999. (Abstract Only)
ZT	ACCC	Tammela, T.L.J., et al., "Temporal changes in micturition and bladder contractility after sucrose diuresis and streptozotocin-induced diabetes mellitus in rats", <i>The Journal of Urology</i> , vol. 153, pp. 2014-2021, 1995.

Examiner Signature 	Date Considered 21 AUGUST 2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13425-122001	Application No. 10/622,055
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Cernerud et al.	
		Filing Date July 17, 2003	Group Art Unit 1614 1624

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
ZT	ADDD	Tokunaga, A., et al., "5-HT _{2A} receptor subtype is involved in the thermal hyperalgesic mechanism of serotonin in the periphery", <i>Pain</i> , vol. 76, pp. 349-355, 1998.
ZT	AEEE	Viola, A.U., et al., "Ritaserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers", <i>Clinical Neurophysiology</i> , vol. 113, pp. 429-434, 2002.
ZT	AFFF	Weinberger, D.R., et al., "Cognitive function in schizophrenia", <i>International Clinical Psychopharmacology</i> , vol. 12(supp.), pp. S29-S36, 1997.
ZT	AGGG	Yoshida, A., et al., "5-hydroxytryptamine receptors, especially the 5-HT ₄ receptor, in guinea pig urinary bladder", <i>Jpn. J. Pharmacol.</i> , vol. 89, pp. 349-355, 2002.

Examiner Signature 	Date Considered 21 AUGUST 2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	